3SBio Inc. (TRSBF)

Market Cap	7.65B +236.4%
Revenue (ttm)	1.27B +7.7%
Net Income	329.24M +42.2%
EPS	0.13 +40.7%
Shares Out	n/a
PE Ratio	23.23
Forward PE	8.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Average Volume	726
Open	2.610
Previous Close	n/a
Day's Range	2.610 - 2.610
52-Week Range	2.223 - 4.740
Beta	0.66
RSI	37.34
Earnings Date	Mar 30, 2026

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 6,268
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRSBF

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY